Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease

Marie C Hogan, Tetyana Masyuk, Eric Bergstralh, Bill Li, Walter K Kremers, Lisa E. Vaughan, Angela Ihrke, Amanda L. Severson, Maria Irazabal Mira, James Glockner, Nicholas F La Russo, Vicente Torres

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years. Patients and Methods Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment (year 2) phases reenrolled in a 2-year open-label extension (OLE) study after being off OctLAR a mean of 8.3 months (original study: July 1, 2007, through June 30, 2013). Participants underwent magnetic resonance imaging at baseline, years 1 and 2, reenrollment, and study completion. Primary end point: change in TLV; secondary end points: changes in total kidney volume, glomerular filtration rate, quality of life (QoL), safety, vital signs, and laboratory parameters. Results Twenty-five participants (59.5%) completed the OLE. Off therapy, TLVs increased a mean ± SD of 3.4%±8.2% per year; after resuming therapy, TLVs decreased a mean ± SD of -4.7%±6.1% per year. Despite regrowth off treatment, overall reductions were observed, with a median (interquartile range) TLV of 4047 mL (3107-7402 mL) at baseline and 3477 (2653-7131 mL) at study completion (-13.2%; P<.001) and with improved health-related QoL. Total kidney volumes increased, and glomerular filtration rates declined from 58.2 mL/min to 54.5 mL/min (n=16) in patients with ADPKD on therapy from baseline to study completion. Conclusion Therapy with OctLAR over 4 years in selected patients with symptomatic PLD arrested PLD progression, alleviating symptoms and improving health-related QoL. Discontinuation led to organ regrowth. Trial Registration clinicaltrials.gov Identifier: NCT00426153.

Original languageEnglish (US)
Pages (from-to)1030-1037
Number of pages8
JournalMayo Clinic Proceedings
Volume90
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Octreotide
Autosomal Dominant Polycystic Kidney
Quality of Life
Glomerular Filtration Rate
Therapeutics
Liver
Kidney
Vital Signs
Polycystic liver disease
Disease Progression
Magnetic Resonance Imaging
Clinical Trials
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease. / Hogan, Marie C; Masyuk, Tetyana; Bergstralh, Eric; Li, Bill; Kremers, Walter K; Vaughan, Lisa E.; Ihrke, Angela; Severson, Amanda L.; Irazabal Mira, Maria; Glockner, James; La Russo, Nicholas F; Torres, Vicente.

In: Mayo Clinic Proceedings, Vol. 90, No. 8, 01.08.2015, p. 1030-1037.

Research output: Contribution to journalArticle

@article{777dbbcf685344c9a082e9ef76d8c49c,
title = "Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease",
abstract = "Objective To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years. Patients and Methods Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment (year 2) phases reenrolled in a 2-year open-label extension (OLE) study after being off OctLAR a mean of 8.3 months (original study: July 1, 2007, through June 30, 2013). Participants underwent magnetic resonance imaging at baseline, years 1 and 2, reenrollment, and study completion. Primary end point: change in TLV; secondary end points: changes in total kidney volume, glomerular filtration rate, quality of life (QoL), safety, vital signs, and laboratory parameters. Results Twenty-five participants (59.5{\%}) completed the OLE. Off therapy, TLVs increased a mean ± SD of 3.4{\%}±8.2{\%} per year; after resuming therapy, TLVs decreased a mean ± SD of -4.7{\%}±6.1{\%} per year. Despite regrowth off treatment, overall reductions were observed, with a median (interquartile range) TLV of 4047 mL (3107-7402 mL) at baseline and 3477 (2653-7131 mL) at study completion (-13.2{\%}; P<.001) and with improved health-related QoL. Total kidney volumes increased, and glomerular filtration rates declined from 58.2 mL/min to 54.5 mL/min (n=16) in patients with ADPKD on therapy from baseline to study completion. Conclusion Therapy with OctLAR over 4 years in selected patients with symptomatic PLD arrested PLD progression, alleviating symptoms and improving health-related QoL. Discontinuation led to organ regrowth. Trial Registration clinicaltrials.gov Identifier: NCT00426153.",
author = "Hogan, {Marie C} and Tetyana Masyuk and Eric Bergstralh and Bill Li and Kremers, {Walter K} and Vaughan, {Lisa E.} and Angela Ihrke and Severson, {Amanda L.} and {Irazabal Mira}, Maria and James Glockner and {La Russo}, {Nicholas F} and Vicente Torres",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2015.05.011",
language = "English (US)",
volume = "90",
pages = "1030--1037",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients with Severe Polycystic Liver Disease

AU - Hogan, Marie C

AU - Masyuk, Tetyana

AU - Bergstralh, Eric

AU - Li, Bill

AU - Kremers, Walter K

AU - Vaughan, Lisa E.

AU - Ihrke, Angela

AU - Severson, Amanda L.

AU - Irazabal Mira, Maria

AU - Glockner, James

AU - La Russo, Nicholas F

AU - Torres, Vicente

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years. Patients and Methods Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment (year 2) phases reenrolled in a 2-year open-label extension (OLE) study after being off OctLAR a mean of 8.3 months (original study: July 1, 2007, through June 30, 2013). Participants underwent magnetic resonance imaging at baseline, years 1 and 2, reenrollment, and study completion. Primary end point: change in TLV; secondary end points: changes in total kidney volume, glomerular filtration rate, quality of life (QoL), safety, vital signs, and laboratory parameters. Results Twenty-five participants (59.5%) completed the OLE. Off therapy, TLVs increased a mean ± SD of 3.4%±8.2% per year; after resuming therapy, TLVs decreased a mean ± SD of -4.7%±6.1% per year. Despite regrowth off treatment, overall reductions were observed, with a median (interquartile range) TLV of 4047 mL (3107-7402 mL) at baseline and 3477 (2653-7131 mL) at study completion (-13.2%; P<.001) and with improved health-related QoL. Total kidney volumes increased, and glomerular filtration rates declined from 58.2 mL/min to 54.5 mL/min (n=16) in patients with ADPKD on therapy from baseline to study completion. Conclusion Therapy with OctLAR over 4 years in selected patients with symptomatic PLD arrested PLD progression, alleviating symptoms and improving health-related QoL. Discontinuation led to organ regrowth. Trial Registration clinicaltrials.gov Identifier: NCT00426153.

AB - Objective To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years. Patients and Methods Twenty-eight of 42 participants in a prospective 2-year clinical trial of OctLAR (40 mg monthly) consisting of double-blind, randomized (year 1) and open-label treatment (year 2) phases reenrolled in a 2-year open-label extension (OLE) study after being off OctLAR a mean of 8.3 months (original study: July 1, 2007, through June 30, 2013). Participants underwent magnetic resonance imaging at baseline, years 1 and 2, reenrollment, and study completion. Primary end point: change in TLV; secondary end points: changes in total kidney volume, glomerular filtration rate, quality of life (QoL), safety, vital signs, and laboratory parameters. Results Twenty-five participants (59.5%) completed the OLE. Off therapy, TLVs increased a mean ± SD of 3.4%±8.2% per year; after resuming therapy, TLVs decreased a mean ± SD of -4.7%±6.1% per year. Despite regrowth off treatment, overall reductions were observed, with a median (interquartile range) TLV of 4047 mL (3107-7402 mL) at baseline and 3477 (2653-7131 mL) at study completion (-13.2%; P<.001) and with improved health-related QoL. Total kidney volumes increased, and glomerular filtration rates declined from 58.2 mL/min to 54.5 mL/min (n=16) in patients with ADPKD on therapy from baseline to study completion. Conclusion Therapy with OctLAR over 4 years in selected patients with symptomatic PLD arrested PLD progression, alleviating symptoms and improving health-related QoL. Discontinuation led to organ regrowth. Trial Registration clinicaltrials.gov Identifier: NCT00426153.

UR - http://www.scopus.com/inward/record.url?scp=84938746888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938746888&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.05.011

DO - 10.1016/j.mayocp.2015.05.011

M3 - Article

C2 - 26166166

AN - SCOPUS:84938746888

VL - 90

SP - 1030

EP - 1037

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -